Tsutomu Takeuchi Selected Research

golimumab

6/2023	Successful treatment of refractory enteritis and arthritis with combination of TNF and IL-6 inhibition in patients with ulcerative colitis.
1/2023	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
1/2020	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
9/2018	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.
6/2017	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
7/2016	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
1/2016	Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study.
9/2013	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks.
6/2012	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tsutomu Takeuchi Research Topics

Disease

294	Rheumatoid Arthritis 04/2024 - 06/2003
51	Infections 11/2023 - 08/2002
25	Systemic Lupus Erythematosus (Libman-Sacks Disease) 02/2024 - 09/2003
23	Immunoglobulin G4-Related Disease 01/2023 - 01/2012
21	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 09/2005
19	Herpes Zoster 09/2023 - 01/2016
17	Inflammation (Inflammations) 01/2024 - 08/2003
17	Necrosis 12/2023 - 07/2011
17	Rheumatic Diseases (Rheumatism) 06/2023 - 01/2007
14	Neoplasms (Cancer) 11/2023 - 12/2002
14	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 08/2005
12	Adult-Onset Still's Disease 03/2024 - 03/2012
12	Pain (Aches) 12/2023 - 05/2012
12	Arthritis (Polyarthritis) 09/2023 - 01/2006
11	Lupus Nephritis 02/2024 - 01/2007
9	Drug-Related Side Effects and Adverse Reactions 02/2024 - 11/2010
9	Fever (Fevers) 05/2021 - 09/2005
9	Cysts 06/2012 - 09/2002
8	Systemic Scleroderma (Systemic Sclerosis) 01/2024 - 01/2007
8	Vasculitis (Vasculitides) 11/2023 - 01/2021
8	COVID-19 07/2023 - 01/2021
7	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 11/2023 - 02/2007
7	Pneumonia (Pneumonitis) 01/2021 - 01/2007
7	Opportunistic Infections (Opportunistic Infection) 01/2021 - 01/2005
6	Fatigue 01/2024 - 01/2017
6	Disease Progression 07/2023 - 12/2017
6	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2023 - 08/2017
6	Connective Tissue Diseases (Connective Tissue Disease) 01/2022 - 03/2013
6	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 10/2021 - 01/2015
6	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 11/2012 - 01/2007
5	Chronic Disease (Chronic Diseases) 12/2023 - 03/2013
5	Ankylosing Spondylitis 11/2023 - 08/2017
5	Psoriatic Arthritis 11/2023 - 08/2017
5	Ulcerative Colitis 10/2023 - 01/2017
5	Giant Cell Arteritis (Horton Disease) 01/2023 - 01/2020
5	Myositis (Idiopathic Inflammatory Myopathies) 01/2021 - 09/2005
5	Nasopharyngitis 01/2019 - 06/2016
5	Arthralgia (Joint Pain) 11/2018 - 07/2011
5	Amebiasis (Amoebiasis) 02/2006 - 08/2003
4	Crohn Disease (Crohn's Disease) 10/2023 - 01/2015
4	Takayasu Arteritis (Arteritis, Takayasu's) 01/2023 - 01/2020

Drug/Important Bio-Agent (IBA)

98	Methotrexate (Mexate)FDA LinkGeneric 12/2023 - 12/2004
50	tocilizumab (atlizumab)FDA Link 03/2024 - 09/2007
40	Antirheumatic Agents (DMARD)IBA 12/2023 - 01/2006
37	Infliximab (Remicade)FDA Link 10/2023 - 01/2005
32	GlucocorticoidsIBA 02/2024 - 02/2003
31	Adalimumab (Humira)FDA Link 11/2023 - 06/2012
30	Interleukin-6 (Interleukin 6)IBA 03/2024 - 06/2004
26	Monoclonal AntibodiesIBA 01/2023 - 10/2003
24	CytokinesIBA 01/2024 - 02/2003
24	Biomarkers (Surrogate Marker)IBA 12/2023 - 01/2009
23	Abatacept (Orencia)FDA Link 06/2023 - 03/2013
22	Etanercept (Enbrel)FDA Link 01/2023 - 12/2002
21	Immunoglobulin G (IgG)IBA 01/2023 - 01/2005
20	baricitinibIBA 01/2024 - 01/2017
20	Janus Kinase InhibitorsIBA 12/2023 - 01/2016
19	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2024 - 01/2005
15	C-Reactive ProteinIBA 02/2023 - 01/2008
14	AntibodiesIBA 03/2024 - 02/2003
14	Tumor Necrosis Factor InhibitorsIBA 11/2023 - 07/2011
14	Rituximab (Mabthera)FDA Link 11/2023 - 01/2007
13	peficitinibIBA 12/2023 - 06/2016
13	GLPG0634IBA 12/2023 - 01/2019
13	Prednisolone (Predate)FDA LinkGeneric 10/2023 - 09/2005
13	Certolizumab Pegol FDA Link 07/2023 - 07/2014
13	AutoantibodiesIBA 01/2023 - 01/2011
12	tofacitinibIBA 12/2023 - 07/2015
12	InterleukinsIBA 01/2022 - 11/2013
11	Tacrolimus (Prograf)FDA LinkGeneric 02/2024 - 02/2009
11	Janus KinasesIBA 10/2023 - 06/2017
11	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2019 - 09/2005
11	EnzymesIBA 11/2018 - 01/2004
10	Proteins (Proteins, Gene)FDA Link 10/2023 - 03/2002
9	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 11/2023 - 01/2011
9	golimumab FDA Link 06/2023 - 06/2012
8	upadacitinibIBA 11/2023 - 01/2020
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2023 - 09/2005
7	Messenger RNA (mRNA)IBA 06/2023 - 09/2003
7	Denosumab FDA Link 11/2021 - 06/2016
7	sirukumabIBA 01/2021 - 06/2017
7	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2020 - 01/2009
6	SteroidsIBA 10/2023 - 05/2015
6	Biosimilar PharmaceuticalsIBA 10/2023 - 06/2017
6	Sulfasalazine (Azulfidine)FDA LinkGeneric 03/2023 - 10/2013
6	omega-Chloroacetophenone (Mace)IBA 01/2023 - 01/2019
6	Leflunomide (Arava)FDA LinkGeneric 01/2023 - 01/2008
6	Immunosuppressive Agents (Immunosuppressants)IBA 11/2021 - 06/2005
6	AntigensIBA 01/2021 - 03/2004
5	sarilumabIBA 12/2023 - 06/2017
5	Rheumatoid FactorIBA 07/2023 - 01/2017
5	DNA (Deoxyribonucleic Acid)IBA 05/2023 - 06/2003
5	quetmolimabIBA 01/2023 - 01/2018
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2023 - 01/2015
4	CT-P13IBA 10/2023 - 01/2015
4	Chemokine CX3CL1IBA 01/2023 - 01/2021
4	Peptides (Polypeptides)IBA 01/2023 - 03/2009
4	Anti-Citrullinated Protein AntibodiesIBA 01/2023 - 06/2014
4	Neutralizing AntibodiesIBA 12/2022 - 08/2003

Therapy/Procedure

97	Therapeutics 02/2024 - 08/2002
5	Biological Therapy 04/2024 - 11/2010